Oxford, UK – 18 December 2019: Vaccitech Ltd announced today that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT), has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer (NSCLC).
{iframe}https://www.vaccitech.co.uk/vaccitech-oncology-limited-enters-collaboration-with-cancer-research-uk-to-fund-a-phase-i-iia-clinical-trial-as-first-line-nsclc-therapy/{/iframe}